HDT Bio's Canadian subsidiary, HDT Bio Canada Inc., has launched a clinical program at McGill University to develop HDT-401, an investigational RNA immune activator for glioblastoma treatment. This is a significant development in the fight against one of the deadliest brain cancers, which currently has a five-year survival rate of below 5%.
The company's partnership with McGill University and The Neuro (Montreal Neurological Institute-Hospital) is a testament to the potential of HDT-401. The drug has already shown encouraging results in compassionate use protocols, leading to the design of a formal Phase 1 clinical trial. HDT Bio Canada has completed a pre-Clinical Trial Application meeting with Health Canada, receiving constructive feedback that advances the program toward CTA submission.
HDT-401 combines Riboxxim, a precisely engineered molecule licensed from Riboxx GmbH, with HDT Bio's proprietary LION™ nucleic acid delivery platform. The LION™ platform has been evaluated in over 6,000 patients across multiple clinical programs, providing a strong foundation of clinical experience.
The drug is designed to activate innate immune sensing directly within the tumor bed, converting the glioblastoma microenvironment from immune-suppressed to immune-engaged. This approach aims to induce inflammatory cytokines, recruit immune effector cells, and support local immune recognition of tumor tissue. Local administration into the tumor or surgical cavity concentrates immune activation at the site of disease while limiting systemic exposure.
The potential of HDT-401 is further emphasized by the commitment of Roberto Diaz, MD, PhD, of The Neuro of McGill University. Dr. Diaz, who operates on glioblastoma patients, understands the challenges of treating this disease and believes that HDT-401 has the potential to change the landscape of glioblastoma treatment.
HDT Bio's commitment to Canada is significant, as the company is developing products in Canada, working through Canadian regulatory pathways, and supporting Canadian manufacturing capability. This commitment is reflected in the company's breast cancer vaccine program, which is being advanced in Canada with the support of Northern RNA Inc., a world-class nucleic acid contract manufacturer.
In conclusion, HDT Bio's Canadian clinical program at McGill University represents a promising step forward in the treatment of glioblastoma. The potential of HDT-401, combined with the company's commitment to Canada, positions HDT Bio as a leader in the development of innovative cancer treatments.
